Atrial Fibrillation Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Atrial Fibrillation stocks.

Atrial Fibrillation Stocks Recent News

Date Stock Title
Nov 22 MDT Medtronic acquires Fortimedix Surgical to boost surgical portfolio
Nov 22 BMY AbbVie Jumps Nearly 4% On An Upgrade Despite Bristol Myers-Tied Setback
Nov 22 MDT MDT Stock Gains From FDA Approval for Its InPen App
Nov 22 MDT Medtronic nets FDA nod for smart insulin pen app
Nov 22 MDT Medtronic buys surgical instrument developer Fortimedix
Nov 21 MDT Healing People and Planet: 3 Things You Need to Know About This Shared Innovation Challenge
Nov 21 BMY Major companies that are also popular short-selling stocks
Nov 21 MDT Here's Why Medtronic (MDT) is a Strong Value Stock
Nov 21 BMY Is Bristol Myers Squibb Stock a Buy?
Nov 21 MDT 3 Dividend Stocks I'll Never Sell
Nov 21 MDT Medtronic’s insulin pen app gains FDA clearance
Nov 21 BMY Want Over $3,000 in Annual Dividends? Invest $20,000 in Each of These 3 Stocks
Nov 20 MDT Medtronic plc (MDT): A Key Player in Ken Griffin’s Portfolio with Steady Growth
Nov 20 MDT Medtronic reports rise in Q2 FY 2025 net income to $1.27bn
Nov 20 MDT Healing People and Planet: New Impact Report Outlines How Medtronic Is Shaping the Future of Health
Nov 20 MDT Medtronic receives FDA clearance for new InPen app
Nov 20 MDT Medtronic receives FDA clearance for new InPen™ app, paving the way for its Smart MDI system launch with Simplera™ CGM
Nov 20 CVKD CVKD: Recent Financings Raise $9.8 Million…
Nov 20 MDT Jim Cramer on Medtronic plc (MDT): ‘It Has Been A Winner’
Nov 20 MDT Medtronic Second Quarter 2025 Earnings: Beats Expectations
Atrial Fibrillation

Atrial fibrillation (AF or A-fib) is an abnormal heart rhythm characterized by rapid and irregular beating of the atria. Often it starts as brief periods of abnormal beating which become longer and possibly constant over time. Often episodes have no symptoms. Occasionally there may be heart palpitations, fainting, lightheadedness, shortness of breath, or chest pain. The disease is associated with an increased risk of heart failure, dementia, and stroke. It is a type of supraventricular tachycardia.High blood pressure and valvular heart disease are the most common alterable risk factors for AF. Other heart-related risk factors include heart failure, coronary artery disease, cardiomyopathy, and congenital heart disease. In the developing world valvular heart disease often occurs as a result of rheumatic fever. Lung-related risk factors include COPD, obesity, and sleep apnea. Other factors include excess alcohol intake, tobacco smoking, diabetes mellitus, and thyrotoxicosis. However, half of cases are not associated with any of these risks. A diagnosis is made by feeling the pulse and may be confirmed using an electrocardiogram (ECG). A typical ECG in AF shows no P waves and an irregular ventricular rate.AF is often treated with medications to slow the heart rate to a near normal range (known as rate control) or to convert the rhythm to normal sinus rhythm (known as rhythm control). Electrical cardioversion can also be used to convert AF to a normal sinus rhythm and is often used emergently if the person is unstable. Ablation may prevent recurrence in some people. For those at low risk of stroke, no specific treatment is typically required, though aspirin or an anti-clotting medication may occasionally be considered. For those at more than low risk, an anti-clotting medication is typically recommended. Anti-clotting medications include warfarin and direct oral anticoagulants. Most people are at higher risk of stroke. While these medications reduce stroke risk, they increase rates of major bleeding.Atrial fibrillation is the most common serious abnormal heart rhythm. In Europe and North America, as of 2014, it affects about 2 to 3% of the population. This is an increase from 0.4 to 1% of the population around 2005. In the developing world, about 0.6% of males and 0.4% of females are affected. The percentage of people with AF increases with age with 0.1% under 50 years old, 4% between 60 and 70 years old, and 14% over 80 years old being affected. A-fib and atrial flutter resulted in 193,300 deaths in 2015, up from 29,000 in 1990. The first known report of an irregular pulse was by Jean-Baptiste de Sénac in 1749. This was first documented by ECG in 1909 by Thomas Lewis.

Browse All Tags